Percivia Information

View Top Employees from Percivia

Percivia | 503 followers on LinkedIn. PERCIVIA is a venture formed by Crucell N.V. and Royal DSM N.V., to develop recombinant therapeutic proteins using the PER.C6® human cell line, with a focus on biosimilar monoclonal antibodies globally. Additionally, PERCIVIA out-licenses the PER.C6® cell line and provides logistical support by training and advising on the methods of recombinant protein production using the technology to licensees. PERCIVIA’s unique advantage lies in the core technologies of PER.C6®, the company’s high yield proprietary human cell line, which enables SCALE™, a market-optimized manufacturing process, allowing for rapid facility set up with an “In Market, For Market”™ manufacturing solution.

Website	http://www.percivia.com
Revenue	$6.6 million
Employees	3 (1 on RocketReach)
Founded	2006
Address	1 Hampshire St Unit 5, Cambridge, Massachusetts 02139, US
Phone	+1 617-301-8800
Technologies	JavaScript , HTML (view technologies)
Industry	Biotechnology, Business Services General, Pharmaceuticals, Business Services, Science and Engineering, Information Technology
Keywords	Biosimilar Development, Recombinant Protein Production, Biologics Manufacturing, Biopharmaceutical Manufacturing, Pharmaceutical Development, Drug Development, Biotechnology, Pharmaceutical Manufacturing, Bioprocessing, Protein Engineering, Cell Culture Technology, Biotechnology Research, Pharmaceutical Research, Global Biopharma
Competitors	Thermo Fisher Scientific, Merck Group, FUJIFILM Diosynth Biotechnologies, Biogen, Lonza, WuXi AppTec, Sartorius, Celerion, Geno, Zymergen, Inc. +51 more (view full list)
SIC	SIC Code 283 Companies, SIC Code 28 Companies, SIC Code 873 Companies, SIC Code 87 Companies
NAICS	NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 325 Companies